Johnson & Johnson volition question authorization for a booster changeable this week, according to The New York Times, which cited unidentified officials acquainted with the company’s plans.
The quality that the institution volition question authorization from the Food and Drug Administration (FDA) comes amid concerns astir the efficacy of its single-shot Covid-19 vaccine.
The FDA has confirmed that its adept advisory committee is scheduled to sermon booster shots for Johnson & Johnson’s vaccine during its meetings connected October 14 and 15.
“The information that the advisory committee gathering connected Johnson & Johnson was scheduled adjacent earlier the institution filed an exertion to the Food and Drug Administration reflects a peculiar consciousness of urgency successful the Biden medication to supply much extortion to recipients of that vaccine,” The New York Times reported, noting that a caller study by the Centers for Disease Control and Prevention (CDC) recovered that Johnson & Johnson’s single-dose vaccine was lone 71% effectual astatine preventing hospitalizations.
Alan is simply a writer, editor, and quality junkie based successful New York.